Disposition of butadiene epoxides in Sprague-Dawley rats

Chemico-Biological Interactions

Volumn 104, Issue 2-3, 1997, Pages 103-115

  Valentine, John L ^a,b   Boogaard, Pieter J ^a,c   Sweeney, Lisa M ^a,d   Turner, Max J ^a   Bond, James A ^a   A Medinsky, Michele ^a  

^a CIIT CENTERS FOR HEALTH RESEARCH   (United States)

^b GENZYME CORPORATION   (United States)

^c SHELL RESEARCH AND TECHNOLOGY CENTRE   (Netherlands)

^d Mfg Technologies Directorate   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTADIENE DIEPOXIDE; EPOXIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; MALE; NONHUMAN; PHARMACOKINETICS; RAT; TOXICOKINETICS;

ANIMALS; AREA UNDER CURVE; CARCINOGENS; CHROMATOGRAPHY, GAS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOXY COMPOUNDS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALF-LIFE; HEMATOCRIT; INJECTIONS, INTRAVENOUS; MALE; MUTAGENS; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE STANDARDS; SOFTWARE;

ANIMALIA; RODENTIA;

EID: 0030965722     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(97)03773-3     Document Type: Article

References (34)

1. L.M. Miller, Investigations of selected potential environmental contaminants: butadiene and its oligomers. EPA-560/2-78-008, U.S. Environmental Protection Agency, Washington, DC. (1978).
2. P.E. Owen, J.R. Glaister, I.F. Gaunt and D.H. Pullinger, Inhalation toxicity studies with 1,3-butadiene. 3. Two year toxicity/carcinogenicity study in rats. Am. J. Ind. Hyg. Assoc. J., 48 (1987) 407-413.
3. C. deMeester, F. Poncelet, M. Roberfroid and M. Mercier, Mutagenicity of butadiene and butadiene monoxide. Biochem. Biophys. Res. Comm., 80 (1978) 298-305.
4. C. deMeester, F. Poncelet, M. Roberfroid and M. Mercier, Mutagenicity of butadiene toward Salmonella typhimurium. Toxicol. Lett., 6 (1980) 125-130.
5. R. Kreiling, R.J. Laib, J.G. Filser and H.M. Bolt, Species differences in butadiene metabolism between mice and rats evaluated by inhalation pharmacokinetics. Arch. Toxicol., 58 (1986) 235-238.
6. J.A. Bond, A.R. Dahl, R.F. Henderson, J.S. Dutcher, J.L. Mauderly and L.S. Birnbaum, Species differences in the disposition of inhaled butadiene. Toxicol. Appl. Pharmacol., 84 (1986) 617-627.
7. M.W. Himmelstein, B. Asgharian and J.A. Bond, High concentrations of butadiene epoxides in livers and lungs of mice compared to rats exposed to 1,3-butadiene. Toxicol. Appl. Pharmacol., 132 (1995) 281-288.
8. M.J. Seaton, M.H. Follansbee, and J.A. Bond, Oxidation of 1,2-epoxy-3-butene to 1,2;3,4-diepoxybutane by cDNA-expressed human cytochromes P450 2E1 and 3A4 and human, mouse and rat liver microsomes. Carcinogenesis 16 (1995) 2287-2293.
9. J.E. Cochrane and T.R. Skopek, Mutagenicity of butadiene and its epoxide metabolites: I. Mutagenic potential of 1,2-epoxybutene, 1,2;3,4-diepoxybutane and 3,4-epoxy-1,2-butanediol in cultured human lymphoblasts. Carcinogenesis 15 (1994) 713-717.
10. J.E. Cochrane and T.R. Skopek, Mutagenicity of butadiene and its epoxide metabolites: II. Mutational spectra of butadiene, 1,2-epoxybutene and diepoxybutane at the hprt locus in splenic T cells from exposed B6C3F1 mice. Carcinogenesis 15 (1994) 719-723.
11. P.G. Gervasi, L. Citti, M. del Monte, V. Longo and D. Benetti, Mutagenicity and chemical reactivity of epoxide intermediates of the isoprene metabolism and other structurally related compounds. Mutat. Res., 156 (1985) 77-82.
12. G.A. Csanády, F.P. Guengerich and J.A. Bond, Comparison of the biotransformation of 1,3-butadiene and its metabolite, 1,2-epoxybutene, by hepatic and pulmonary tissues from humans, rats, and mice. Carcinogenesis 13 (1992) 1143-1153.
13. J.E. Sharer and A.A. Elfarra, S-(2-hydroxy-3-buten-1-yl) glutathione and S-(1-hydroxy-3-buten-2-yl) glutathione are in vivo metabolites of butadiene monoxide: Detection and quantitation in bile. Chem. Res. Toxicol., 5 (1992) 787-790.
14. J.R. Thornton-Manning, A.R. Dahl, W.E. Bechtold, W.C. Griffith Jr. and R. Henderson, Disposition of 1,2-epoxybutene and diepoxybutane in various tissues of rats and mice following a low-level inhalation exposure to 1,3-butadiene. Carcinogenesis 16 (1995) 1723-1731.
15. M.W. Himmelstein, M.J. Turner, B. Asgharian and J.A. Bond, Comparison of blood concentrations of 1,3-butadiene and butadiene epoxides in mice and rats exposed to 1,3-butadiene by inhalation. Carcinogenesis 15 (1994) 1479-1486.
16. W.E. Bechtold, M.R. Strunk, J.R. Thornton-Manning and R.F. Henderson, Analysis of butadiene, butadiene monoxide, and butadiene dioxide in blood by gas chromatography/gas chromatography/mass spectroscopy. Chem. Res. Toxicol., 8 (1995) 182-187.
17. P.J. Boogaard and J.A. Bond, The role of hydrolysis in the detoxification of 1,2;3,4-diepoxybutane by human, rat, and mouse liver and lung in vitro. Toxicol. App. Pharmacol., 141 (1996) 617-627.
18. W.J. Jusko, Guidelines for collection and analysis of pharmacokinetic data, in: W.E. Evans, J.J. Schentag and W.J. Jusko (Eds.) Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 1992, pp. 2-1-2-43.
19. C.C. Peck, L.B. Sheiner, A.I. Nichols, The problem of choosing weights in nonlinear regression analysis of pharmacokinetic data. Drug Metab. Rev., 15 (1984) 133-148.
20. H.G. Boxenbaum, S. Riegelman and R.M. Elashoff, Statistical estimations in pharmacokinetics. J. Pharmacokinet. Biopharm., 2 (1974) 123-148.
21. M. Gibaldi and D. Perrier, Pharmacokinetics, Marcel Dekker, NY, 1982.
22. P.L. Altman, (Ed.) Blood and Other Body Fluids, In: Federation of American Societies for Experimental Biology. 1961, p. 359.
23. Y. Kato, J. Hirate, K. Sakaguchi, M. Ueno and I. Horikoshi, Age-dependent change in warfarin distribution volume in rats: Effect of change in extracellular water volume. J. Pharmacobio-Dyn., 10 (1987) 330-335.
24. L.J. Brunner, J.T. Dipiro and S. Feldman, Metabolic cage isolation reduces antipyrine clearance in rats. J. Pharm. Pharmacol., 46 (1994) 581-584.
25. M. Rowland and T.N. Tozer (Eds.) Clinical Pharmacokinetics, Lea and Febiger, Philadelphia, 1989 P. 22.
26. S. Osterman-Golkar and J.A. Bond, Biomonitoring of 1,3-butadiene and related compounds. Environ. Health Perspect 104 (1996) 107-915.
27. M.A. Medinsky, T.L. Leavens, G.A. Csanády, M.L. Gargas and J.A. Bond, In vivo metabolism of butadiene by mice and rats: a comparison of physiological model predictions and experimental data. Carcinogenesis 15 (1994) 1329-1340.
28. L.M. Sweeney, P.M. Schlosser, M.A. Medinsky and J.A. Bond, Physiologically based pharmacokinetic modeling of 1,3-butadiene, 1,2-epoxy-3-butene, and 1,2:3,4-diepoxybutane toxicokinetics in mice and rats. Carcinogenesis 18 (1997) 000-000.
29. 13C]butadiene. Chem. Res. Toxicol., 9 (1996) 764-773.
30. P.J. Boogaard and J.A. Bond, The role of hydrolysis in the detoxification of 1,2:3,4-diepoxybutane by human, rat, and mouse liver and lung in vitro. Toxicol. Appl. Pharmacol., 141 (1996) 617-627.
31. A.A. Elfarra, J.E. Sharer and R.J. Duescher, Synthesis and characterization of N-acetyl-L-cysteine S-conjugates of butadiene monoxide and their detection and quantitation in urine of rats and mice given butadiene monoxide. Chem. Res. Toxicol., 8 (1995) 68-76.
32. S. Osterman-Golkar, A. Kautiainen, E. Bergmark, K. Håkansson and J. Mäki-Paakkanen, Hemoglobin adducts and urinary mercapturic acids in rats as biological indicators of butadiene exposure. Chem.-Biol. Interact., 80 (1991) 291-302.
33. International Life Sciences Institute and the Risk Science Institute Working Group, Physiological parameter values for PBPK models. ILSI RSI Working Group. Washington, D.C., 1994, 103 pp.
34. H.M. Bolt, G. Schmiedel, J.G. Filser, H.P. Rolzhauser, K. Lieser, D. Wistuba and V. Schurig, Biological activation of 1,3-butadiene to vinyl oxirane by rat liver microsomes and expiration of the reactive metabolite by exposed rats. Cancer Res. Clin. Oncol., 106 (1983) 112-116.